Compared with the robust antitumor efficacy reported for combination therapy using anti-PD-1 (or anti-PD-L1) and anti-Tim-3 antibodies (45, 46), the hybrid nanovesicles in our study demonstrated relatively modest tumor suppression. This evidence concerns the gene PDCD1 and neoplasm.